Abstract
The in vitro susceptibility of 27 clinical isolates ofHelicobacter pylori to erythromycin, clarithromycin, azithromycin and temafloxacin under various pH conditions was evaluated. Clarithromycin (MIC90 0.03 µg/ml) was found to be significantly more active than either erythromycin (MIC90 0.125 µg/ml) or azithromycin (MIC90 0.25 µg/ml) at a neutral pH. Lowering the pH to 5.75 resulted in a loss in efficacy from 8- to 32-fold for all three macrolides studied. The MIC90 of clarithromycin (0.5 µg/ml) remained lower than those of azithromycin (2 µg/ml) and erythromycin (4 µg/ml). No synergism or antagonism was observed with combinations of clarithromycin and temafloxacin at either the neutral or lower pH values.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Rollason TP, Stone J, Rhodes JM: Spiral organisms in endoscopic biopsies of the human stomach. Journal of Clinical Pathology 1984, 37: 23–26.
Bayerdorffer E, Ottenjann R: The role of antibiotics inCampylobacter pylori associated peptic ulcer disease. Scandinavian Journal of Gastroenterology, 1988, 142, Supplement: 93–100.
Shungu DL, Nalin DR, Gilman RH, Gadebusch HH, Cerami AT, Gill C, Weissberger B: Comparative susceptibilities ofCampylobacter pylori to norfloxacin and other agents. Antimicrobial Agents and Chemotherapy 1987, 31: 949–950.
Czinn S, Carr H, Aronoff S: Susceptibility ofCampylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin. Antimicrobial Agents and Chemotherapy 1986, 30: 328–329.
Hardy DJ, Hanson CW, Hensey DM, Beyer JM, Fernandes PB: Susceptibility ofCampylobacter pylori to macrolides and fluoroquinolones. Journal of Antimicrobial Chemotherapy 1988, 22: 631–636.
Nagate T, Numata K, Hanada K, Kondo I: The susceptibility ofCampylobacter pylori to antiulcer agents and antibiotics. Journal of Clinical Gastroenterology 1990, 12, Supplement 1: 135–138.
Czinn SJ, Carr H, Hupertz V: Susceptibility ofCampylobacter pylori to newer cephalosporin antibiotics. Chemotherapy 1989, 35: 164–167.
Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC: Effect of varying pH on the susceptibility ofCampylobacter pylori to antimicrobial agents. European Journal of Clinical Microbiology & Infectious Diseases 1989, 8: 888–889.
McNulty CAM, Gearty JC, Crump B, Davis M, Donovan IA, Melikian V, Lister DM, Wise R:Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth saliccylate and erythromycin ethylsuccinate. British Medical Journal 1986, 293: 645–649.
Stone JW, Wise R, Donovan IA, Gearty J: Failure of ciprofloxacin to irradicateCampylobacter pylori from the stomach. Journal of Antimicrobial Chemotherapy 1988, 22: 92–93.
McNulty CA, Dent JC, Ford GA, Wilkinson SP: Inhibitory antimicrobial concentrations againstCampylobacter pylori in gastric mucosa. Journal of Antimicrobial Chemotherapy 1988, 22: 729–738.
Glupczynski Y, Burette A: Failure of azithromycin to eradicateCampylobacter pylori from the stomach because of acquired resistance during treatment. American Journal of Gastroenterology 1990, 85: 98–99.
Logan RPH, Gummett PA, Hegarty BT, Walker MM, Baron JH, Misiewicz JJ: Clarithromycin and omeperazole forHelicobacter pylori. Lancet 1992, 340: 239.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Malanoski, G.J., Eliopoulos, G.M., Ferraro, M.J. et al. Effect of pH variation on the susceptibility ofHelicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 12, 131–133 (1993). https://doi.org/10.1007/BF01967591
Issue Date:
DOI: https://doi.org/10.1007/BF01967591